Nanoparticles used in medical applications for the lung: hopes for nanomedicine and fears for nanotoxicity

Boland, Sonja; Guadagnini, Rina; Baeza‐Squiban, Armelle; Hussain, Salik; Marano, Francelyne

doi:10.1088/1742-6596/304/1/012031

Cited by 7 publications

(5 citation statements)

References 57 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Nanotechnology provides a new dimension to the targeted drug-delivery approach, with multiple benefits in COPD. However, nanomaterials for transporting therapeutics need to be assessed for the potential health hazards, especially since different nanoparticles have been demonstrated to induce toxicity related to their nanometre size, opening a the new field of nanotoxicology [ 149 ]. Nanoparticles also generate and contribute to oxidative stress via direct and indirect cellular interactions.…”

Section: Introductionmentioning

confidence: 99%

Novel drug delivery systems targeting oxidative stress in chronic obstructive pulmonary disease: a review

Song

2020

J Nanobiotechnol

View full text Add to dashboard Cite

Oxidative stress is significantly involved in the pathogenesis and progression of chronic obstructive pulmonary disease (COPD). Combining antioxidant drugs or nutrients results in a noteworthy therapeutic value in animal models of COPD. However, the benefits have not been reproduced in clinical applications, this may be attributed to the limited absorption, concentration, and half-life of exogenous antioxidants. Therefore, novel drug delivery systems to combat oxidative stress in COPD are needed. This review presents a brief insight into the current knowledge on the role of oxidative stress and highlights the recent trends in novel drug delivery carriers that could aid in combating oxidative stress in COPD. The introduction of nanotechnology has enabled researchers to overcome several problems and improve the pharmacokinetics and bioavailability of drugs. Large porous microparticles, and porous nanoparticle-encapsulated microparticles are the most promising carriers for achieving effective pulmonary deposition of inhaled medication and obtaining controlled drug release. However, translating drug delivery systems for administration in pulmonary clinical settings is still in its initial phases.

show abstract

Section: Introductionmentioning

confidence: 99%

Novel drug delivery systems targeting oxidative stress in chronic obstructive pulmonary disease: a review

Song

2020

J Nanobiotechnol

View full text Add to dashboard Cite

show abstract

“…Dudhat and Patel from air/blood boundary is anyway considerably other noticeable to the alveolar epithelium [108].…”

Section: Fig 4: General Route Of Administration Of Nanoparticles Formentioning

confidence: 97%

“…Encouraged intersection of the coating liquids and endocytosis of NDS will enhance transfection efficiencies. Especially essential target cells are epithelial cells, neutrophils (e.g., in COPD), and eosinophils (e.g., in asthma) [108]. By targeting NPs other than the oral route, the rate of excretion will be decreased through bypass first metabolism.…”

Section: Rational For Development Of Np Dosage For Ipfmentioning

confidence: 99%

See 1 more Smart Citation

Novel Nanoparticulate Systems for Idiopathic Pulmonary Fibrosis: A Review

Dudhat

Patel

2020

Asian J Pharm Clin Res

View full text Add to dashboard Cite

Idiopathic pulmonary fibrosis (IPF) is the model of a substantial and heterogeneous gathering of pneumonic issues, mostly constant and dynamic, normally known as interstitial lung disease. In the course of the most recent couple of decades, IPF has been progressively perceived as a noteworthy neglected therapeutic need in respiratory pharmaceutical and has turned into the focal point of exceptional research action. This is because of the ways that IPF frequency is expanding around the world, with rates (and sadly forecast) that are fundamentally the same as those of numerous types of growth. Clinical research on IPF has been gigantically progressing, coming full circle in the current revelation of two sheltered and compelling medications, now at long last made accessible to patients. Ordinary treatment for lung disease is related to the absence of specificity and access to the typical cells bringing about cytotoxicity, lessened cell take-up, tranquilize obstruction, and quick medication freedom from the body. The rise of nanotechnology has reformed the treatment of lung diseases like IPF. The focal point of nanotechnology is to target abnormal alveolar epithelial cells (AECs) with enhanced bioavailability and diminished poisonous quality. Nanoparticulates have the potential for IPF treatment by increasing particular access to the abnormal AECs because of surface modifiability and littler size. This audit article additionally features the attributes, ongoing advances in the planning of NPs, and helpful results.

show abstract

“…However, nanomaterials for therapeutic delivery must be investigated for possible health risks, particularly as distinct NPs are reported to induce toxicity in proportion to their nanometer size, spawning a new area called nanotoxicology. 65 Through direct and indirect biological interactions, NPs also contribute to oxidative stress. The interaction of nanoparticles with interior cellular components can cause oxidation, which worsens the severity of oxidative stress.…”

Section: Application Of Ndds In Corticosteroid-resistant Asthmamentioning

confidence: 99%

Immune Repertoire and Advancements in Nanotherapeutics for the Impediment of Severe Steroid Resistant Asthma (SSR)

Beeraka¹,

Zhou²,

Wang³

et al. 2022

IJN

View full text Add to dashboard Cite

Severe steroid-resistant asthma (SSR) patients do not respond to the corticosteroid therapies due to the heterogeneity, and genome-wide variations. However, there are very limited reports pertinent to the molecular signaling underlying SSR and making pharmacologists, and formulation scientists to identify the effective therapeutic targets in order to produce novel therapies using novel drug delivery systems (NDDS). We have substantially searched literature for the peer-reviewed and published reports delineating the role of glucocorticoid-altered gene expression, and the mechanisms responsible for SSR asthma, and NDDS for treating SSR asthma using public databases PubMed, National Library of Medicine (NLM), google scholar, and medline. Subsequently, we described reports underlying the SSR pathophysiology through several immunological and inflammatory phenotypes. Furthermore, various therapeutic strategies and the role of signaling pathways such as mORC1-STAT3-FGFBP1, NLRP3 inflammasomes, miR-21/PI3K/HDAC2 axis, PI3K were delineated and these can be considered as the therapeutic targets for mitigating the pathophysiology of SSR asthma. Finally, the possibility of nanomedicine-based formulation and their applications in order to enhance the long term retention of several antioxidant and anti-asthmatic drug molecules as a significant therapeutic modality against SSR asthma was described vividly.

show abstract

Nanoparticles used in medical applications for the lung: hopes for nanomedicine and fears for nanotoxicity

Cited by 7 publications

References 57 publications

Novel drug delivery systems targeting oxidative stress in chronic obstructive pulmonary disease: a review

Novel drug delivery systems targeting oxidative stress in chronic obstructive pulmonary disease: a review

Novel Nanoparticulate Systems for Idiopathic Pulmonary Fibrosis: A Review

Immune Repertoire and Advancements in Nanotherapeutics for the Impediment of Severe Steroid Resistant Asthma (SSR)

Contact Info

Product

Resources

About